Clinical trial
A Placebo Controlled, Double-blind, Randomised Trial for Assessment of the Efficacy of Naoxintong Capsules in the Treatment of Coronary Atherosclerotic Plaque in Patients With Acute Myocardial Infarct on the Basis of Optimal Medical Therapy (Aspirin,Statins, Clopidogrel, Etc.)
NCT05278182 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences, Fuwai Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Placebo Controlled, Double-blind, Randomised Trial for Assessment of the Efficacy of Naoxintong Capsules in the Treatment of Coronary Atherosclerotic Plaque in Patients With Acute Myocardial Infarct on the Basis of Optimal Medical Therapy (Aspirin,Statins, Clopidogrel, Etc.)
- Lead sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- December 31, 2022
- Completion date
- June 30, 2025
- Enrollment
- 80 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
atherosclerotic cardiovascular disease